The board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark.

As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark.

The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.